As artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
Novartis licenses BoomRay radioligand asset for $900M
Latest NewsNovartis has licensed an undisclosed preclinical radioligand therapy from China’s BoomRay Pharmaceuticals in a deal worth up to $900 million (€786 million), adding another asset to one of the pharma group’s core oncology platforms.
Beacon’s XLRP gene therapy meets pivotal U.S. endpoint
Latest NewsBeacon Therapeutics’ gene therapy laru-zova met its U.S. pivotal endpoint in X-linked retinitis pigmentosa, while results on the trial’s separately designated European primary efficacy measure were less clear-cut.
Telix to acquire ITM for $1.65B in radiopharma push
Latest NewsAustralian radiopharma company Telix Pharmaceuticals has agreed to acquire Munich-based ITM Isotope Technologies for an initial $1.65 billion (€1.44 billion), combining Telix’s commercial radiopharma business with one of Europe’s largest producers of therapeutic radioisotopes.
Matisse raises €14M for Phase 2 sepsis trial
Latest NewsDutch biotech Matisse Pharmaceuticals has raised €14 million in a Series A financing to advance isupartob sodium through Phase 2 development in sepsis.
Novartis drops TREM2 antibody in ALS after Phase 2 miss
Latest NewsNovartis has stopped developing its TREM2 antibody VHB937 (lifonebart) in amyotrophic lateral sclerosis (ALS) after the 251-patient Phase 2 ASTRALS trial missed its primary and secondary endpoints, and shortly after Axoltis Pharma suffered a similar Phase 2 setback.
Novartis pays $125M for Sironax brain delivery platform
Latest NewsNovartis is paying $125 million (€106 million) to acquire global rights to Sironax’s brain delivery platform, exercising an option it secured from the U.S.-Chinese biotech in July 2025. Sironax will retain rights to use the technology for selected assets.
Orbis lands $1.4B macrocycle partnership with Novo
Latest NewsNovo has entered a collaboration and licensing agreement with Danish biotech Orbis Medicines worth up to $1.4 billion (€1.2 billion) to discover oral macrocycle drugs for cardiometabolic diseases. Novo will also make an undisclosed strategic investment in Orbis.
Roche taps Dualitas in $1B bispecific deal
Latest NewsRoche will pay Dualitas Therapeutics $36.5 million upfront in a research collaboration that could be worth up to $1 billion to discover bispecific antibodies for immune and inflammatory diseases.
SLAS Journals Spotlight AI in Drug Discovery
Sponsored PublicationsAs artificial intelligence reshapes life sciences research, two leading Elsevier Gold Open Access peer-reviewed journals, SLAS Discovery and SLAS Technology, invite contributions to Special Issues exploring how AI, automation and self-driving laboratories are transforming drug discovery. Submissions are accepted until 15 December 2026.
Sensorion files confidentially for potential U.S. IPO
Latest NewsThe French hearing-loss biotech has taken the first formal step toward a potential U.S. listing, as it advances its remaining gene therapy program into the clinic.